表柔比星对晚期耐药性子宫内膜癌患者的影响分析  

Analysis of the Effect of Epirubicin on Patients with Advanced Drug-resistant Endometrial Cancer

作　　者：王琛 邵世清 王宁 Wang Chen;Shao Shiqing;Wang Ning(Department of Obstetrics and Gynecology,Huaihe Hospital,Henan University,Kaifeng 475000)

机构地区：[1]河南大学淮河医院妇产科,开封475000

出　　处：《数理医药学杂志》2021年第10期1512-1514,共3页Journal of Mathematical Medicine

摘　　要：目的:探讨表柔比星对晚期耐药性子宫内膜癌患者的影响。方法:选择某院2018年10月~2019年10月期间收治的80例晚期耐药性子宫内膜癌患者,采用按随机数字表法分为对照组和观察组各40例,对照组应用氟尿嘧啶联合顺铂化疗,观察组应用表柔比星联合顺铂化疗,均治疗4个疗程。比较两组临床疗效、两组治疗前及治疗4个疗程后的血清卵巢癌抗原(CA125)、脂联素(APN)水平,统计两组毒副反应的发生情况。结果:观察组临床治疗总有效率为60.00%,高于对照组的37.50%(P<0.05);治疗4个疗程后,两组CA125水平均比治疗前降低,APN水平均比治疗前升高,且观察组CA125水平(38.24±4.13)U/L低于对照组(49.35±4.98)U/L,APN水平(8.51±0.91)ug/mL高于对照组(7.31±0.94)ug/mL(P<0.05);观察组毒副反应发生率为7.50%,低于对照组的27.50%(P<0.05)。结论:比起应用氟尿嘧啶联合顺铂,对晚期耐药性子宫内膜癌患者应用表柔比星注射液联合顺铂化疗,可有效降低CA125,增加APN,延缓病情,且具有安全性,值得推广。Objective:To investigate the effect of epirubicin on patients with advanced drug-resistant endometrial cancer.Methods:A total of 80 patients with advanced drug-resistant endometrial cancer admitted to a hospital from October 2018 to October 2019 were selected and divided into 2 groups according to the random number table method,with 40 cases in each group.The control group was treated with fluorouracil combined with cisplatin chemotherapy,and the observation group was treated with epirubicin combined with cisplatin chemotherapy,both of which were treated for 4 courses.The clinical efficacy,serum ovarian cancer antigen(CA125)and adiponectin(APN)levels before and after 4 courses of treatment were compared between the two groups,and the incidence of toxic and side effects in the two groups was counted.Results:The total effective rate of clinical treatment in the observation group was 60.00%,which was higher than 37.50%in the control group(P<0.05).After 4 courses of treatment,the CA125 level of the two groups was lower than before treatment,and the APN level was higher than before treatment.The CA125 level of the observation group(38.24±4.13)U/L was lower than that of the control group(49.35±4.98)U/L,and the APN level in the observation group(8.51±0.91)ug/mL was higher than that in the control group(7.31±0.94)ug/mL(P<0.05).The incidence of side effects in the observation group was 7.50%,which was lower than 27.50%in the control group(P<0.05).Conclusion:Compared with the application of fluorouracil+cisplatin,epirubicin injection+cisplatin chemotherapy for patients with advanced drug-resistant endometrial cancer can effectively reduce CA125,increase APN,and delay the disease,which is safe and worthy of promotion.

关 键 词：晚期耐药性子宫内膜癌 表柔比星 卵巢癌抗原 脂联素 毒副反应 

分 类 号：R737.33[医药卫生—肿瘤]